USPH241220P140000
- 0.00
- 0.000.00%
US Physical Therapy Newsroom
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)
JMP Securities Initiates US Physical Therapy(USPH.US) With Buy Rating, Announces Target Price $113
US Physical Therapy Is Maintained at Outperform by Barrington Research
US Physical Therapy Analyst Ratings
Barrington Maintains US Physical Therapy(USPH.US) With Buy Rating, Maintains Target Price $108
Barrington Maintains US Physical Therapy(USPH.US) With Buy Rating, Maintains Target Price $108
Barrington Research Maintains Outperform on US Physical Therapy, Maintains $108 Price Target
US Physical Therapy Analyst Ratings
BofA Securities Maintains US Physical Therapy(USPH.US) With Hold Rating
US Physical Therapy (USPH) Receives a Hold From Bank of America Securities
US Physical Therapy Is Maintained at Outperform by Barrington Research
US Physical Therapy Analyst Ratings
Barrington Maintains US Physical Therapy(USPH.US) With Buy Rating, Maintains Target Price $108
BofA Securities Maintains US Physical Therapy(USPH.US) With Hold Rating, Maintains Target Price $90
William Blair Initiates US Physical Therapy(USPH.US) With Hold Rating
US Physical Therapy Cut to Neutral From Buy by B of A Securities
BofA Securities Downgrades US Physical Therapy(USPH.US) to Hold Rating, Cuts Target Price to $90
US Physical Therapy Analyst Ratings
Barrington Research Maintains Outperform on US Physical Therapy, Maintains $108 Price Target
Barrington Maintains US Physical Therapy(USPH.US) With Buy Rating, Maintains Target Price $108